84 related articles for article (PubMed ID: 24940695)
1. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
Christopherson RI; Mactier S; Almazi JG; Kohnke PL; Best OG; Mulligan SP
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):375-83. PubMed ID: 24940695
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI
Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291
[TBL] [Abstract][Full Text] [Related]
3. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
Almazi JG; Alomari M; Belov L; Best OG; Shen Y; Graham ME; Mulligan SP; Christopherson RI
Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):314-320. PubMed ID: 34886743
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
Henrich S; Gez S; Crossett B; Mulligan SP; Christopherson RI
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):634-40. PubMed ID: 18600519
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.
Mactier S; Henrich S; Che Y; Kohnke PL; Christopherson RI
J Proteome Res; 2011 Mar; 10(3):1030-42. PubMed ID: 21182289
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.
Kohnke PL; Mactier S; Almazi JG; Crossett B; Christopherson RI
J Proteome Res; 2012 Sep; 11(9):4436-48. PubMed ID: 22839105
[TBL] [Abstract][Full Text] [Related]
8. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
Bastin-Coyette L; Cardoen S; Smal C; de Viron E; Arts A; Amsailale R; Van Den Neste E; Bontemps F
Biochem Pharmacol; 2011 Mar; 81(5):586-93. PubMed ID: 21168391
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Robertson LE; Denny AW; Huh YO; Plunkett W; Keating MJ; Nelson JA
Cancer Chemother Pharmacol; 1996; 37(5):445-50. PubMed ID: 8599867
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
[TBL] [Abstract][Full Text] [Related]
12. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
[TBL] [Abstract][Full Text] [Related]
13. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
14. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
15. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Taguchi H
Leukemia; 2007 May; 21(5):1044-9. PubMed ID: 17344917
[TBL] [Abstract][Full Text] [Related]
17. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
18. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
[TBL] [Abstract][Full Text] [Related]
20. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
